
    
      Patients will be included after signing informed consent. After inclusion, patients will
      continue on standard dosing schedule of guselkumab (i.e. one loading dose (100 mg) at week 0
      and week 4 and followed by subcutaenously injections every 8 weeks). During each study visit
      blood will be taken in order to quantify Ctroughs and/or anti-drug antibodies towards
      guselkumab. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global
      Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology
      Life Quality Index (DLQI) and European quality of life EQ-5D instrument at each visit.
    
  